clinical trial · NCT04111497
Glasdegib for Chronic Graft-Versus-Host Disease
Fred Hutchinson Cancer Center·phase2·terminated·n = 15
Chronic Graft Versus Host DiseaseFasciitisGlasdegib
brief summary
This phase I/II trial studies whether glasdegib is helpful in treating sclerosis associated with chronic graft-versus-host disease. It will also investigate the safety of glasdegib in treating patients with chronic graft-versus-host disease.
started
Dec 3, 2019
primary completion
Aug 23, 2023
completion
Aug 23, 2023
last updated
Oct 29, 2024
detailed description
OUTLINE: This is a phase I/II study.
Patients receive glasdegib orally (PO) once daily (QD) on days 1-28. Cycles repeat every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
official title
A Single-Arm, Open-Label, Phase I/II Study of Glasdegib for Sclerotic Chronic Graft-Vs-Host Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol